Stefan Sperl
Director de Operaciones en KIORA PHARMACEUTICALS, INC. .
Perfil
Stefan Sperl is the founder of Panoptes Pharma GmbH, which was founded in 2013.
He held the title of Chief Operating Officer at the company.
Currently, he is the Executive Vice President-CMC & Operations at Kiora Pharmaceuticals, Inc. He previously worked as a Project Manager at Nabriva Therapeutics GmbH.
Dr. Sperl obtained a doctorate degree from the Max Planck Institute of Biochemistry.
Cargos activos de Stefan Sperl
Empresas | Cargo | Inicio |
---|---|---|
KIORA PHARMACEUTICALS, INC. | Director de Operaciones | - |
Antiguos cargos conocidos de Stefan Sperl.
Empresas | Cargo | Fin |
---|---|---|
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Corporate Officer/Principal | - |
Panoptes Pharma GmbH
Panoptes Pharma GmbH BiotechnologyHealth Technology Panoptes Pharma GmbH develops molecule drugs to treat eye diseases. The firm focuses on a new treatment for autoimmune uveitis, a disease which is one of the major causes of blindness. The company was founded by Franz Obermayr and Stefan Sperl in July 2013 and is headquartered in Wien, Austria. | Fundador | - |
Formación de Stefan Sperl.
Max Planck Institute of Biochemistry | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
KIORA PHARMACEUTICALS, INC. | Health Technology |
Empresas privadas | 2 |
---|---|
Panoptes Pharma GmbH
Panoptes Pharma GmbH BiotechnologyHealth Technology Panoptes Pharma GmbH develops molecule drugs to treat eye diseases. The firm focuses on a new treatment for autoimmune uveitis, a disease which is one of the major causes of blindness. The company was founded by Franz Obermayr and Stefan Sperl in July 2013 and is headquartered in Wien, Austria. | Health Technology |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Health Technology |
- Bolsa de valores
- Insiders
- Stefan Sperl